Dongguan, China

Mingyu Guan

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2017.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Mingyu Guan in CDK Inhibition

Introduction

Mingyu Guan is a notable inventor based in Dongguan, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as cyclin-dependent kinase (CDK) inhibitors. His work focuses on addressing critical health issues related to inflammation and cell proliferation diseases.

Latest Patents

Mingyu Guan holds a patent for "2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof." This invention provides compounds that act as small-molecule inhibitors of CDK, specifically targeting CDK 4 and CDK 6. The novel compounds developed by Guan have the potential to be used in treating various diseases associated with inflammation and abnormal cell growth. He has 1 patent to his name.

Career Highlights

Mingyu Guan is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in developing CDK inhibitors has positioned him as a key player in the industry, contributing to advancements in therapeutic options for patients.

Collaborations

Mingyu has collaborated with several talented individuals in his field, including Bing Liu and Yingjun Zhang. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Mingyu Guan's work in the development of CDK inhibitors represents a significant advancement in the treatment of inflammation and cell proliferation diseases. His innovative approach and dedication to research continue to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…